Samsung Bioepis launches ARMD biosimilar drug in Germany, Canada

The S.Korean company sold $4.3 million worth of SB11, a treatment of eye diseases, in the US in 2022

Researchers of Samsung Bioepis(Courtesy of Samsung Bioepis)
Researchers of Samsung Bioepis(Courtesy of Samsung Bioepis)
Jeong Min Nam 1
2023-03-06 10:11:32 peux@hankyung.com
Bio & Pharma

Samsung Bioepis Co., a South Korean biosimilar firm, announced on Sunday that it has recently launched a new biosimilar drug called SB11 for the treatment of eye diseases, including age-related macular degeneration (ARMD), in Germany and Canada.

The drug was released on Feb. 23 in Germany and on Mar. 1 in Canada, and local sales are being handled by US-based multinational biotech company Biogen Inc.

SB11 is a biosimilar of Lucentis, a drug developed by global pharmaceutical company Genentech. It is marketed under the name Byooviz in Europe and the US, and Amelivu in Korea. It was released in Korea in January last year and in the United States in June last year, with sales in the US reaching $4.3 million.

Samsung Bioepis aims to expand the availability of SB11 in other European countries as well.

"We will establish a competitive edge in the ophthalmic disease treatment biosimilar market by proactively launching the drug," said a company official.

Write to Jeong Min Nam at peux@hankyung.com
#Samsung Bioepis #age-related macular degeneration #ARMD #SB11 #Biogen #Lucentis #korea samsung bioepis #samsung bioepis armd

Samsung Bioepis sees greater market for Byooviz eye disease biosimilar

Samsung Bioepis sees greater market for Byooviz eye disease biosimilar

Samsung Bioepis headquarters  NEW YORK – Samsung Bioepis Co., a biopharmaceutical unit of South Korea’s top conglomerate Samsung, is one step ahead of its rivals in the eye disease-related biosimilar segment, particularly for the treatment of macular degeneration, the global ma

Samsung Bioepis’ SB12 shows same clinical effects as Alexion’s Solaris

Samsung Bioepis’ SB12 shows same clinical effects as Alexion’s Solaris

A researcher at Samsung Bioepis conducts a drug test Samsung Bioepis Co., a biopharmaceutical unit of Samsung Group, said its SB12, a proposed biosimilar to Alexion Pharmaceuticals Inc.’s rare blood disease medicine, Solaris, has shown the same clinical effects.While presenting the result

Samsung Bioepis to double biosimilars, may resume Nasdaq listing plans

Samsung Bioepis to double biosimilars, may resume Nasdaq listing plans

A researcher at Samsung Bioepis conducts a drug test Samsung Bioepis Co., a biopharmaceutical unit of Samsung Group, plans to double the number of its biosimilar products on sale to 10 by 2025 and accelerate its push for the development of novel therapeutics.With its increasing biosimilar reven

Samsung Bioepis posts $1.26 billion in global biosimilar sales

Samsung Bioepis posts $1.26 billion in global biosimilar sales

A Samsung Bioepis researcher Samsung Bioepis Co., a biopharmaceutical unit of Samsung Group, said on Friday that sales of its five biosimilar products in global markets, excluding South Korea, reached $1.26 billion in 2021, up 11% from the previous year.In 2020, global sales of the company&rsqu
(* comment hide *}